Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

BIO picks Russell Reynolds

  • News

Executive Summary

Biotechnology Industry Organization selects Russell Reynolds Associates to lead search for successor to President Carl Feldbaum (1"The Pink Sheet" Feb. 9, 2004, p. 12). The search firm has worked with the Pharmaceutical Research & Manufacturers of America, which is also looking for a new president. PhRMA had been working on a deal with Rep. Billy Tauzin (R-La.), but he has ended the discussions (2"The Pink Sheet" March 1, 2004, p. 23)...

You may also be interested in...



PhRMA CEO Search On Hold; Tauzin Will Wait On Decision

Rep. Billy Tauzin (R-La.) has suspended discussions with the Pharmaceutical Research & Manufacturers of America to become the trade association's CEO, his office said Feb. 26

BIO Begins Search For New President; Feldbaum To Step Down By End Of Year

The Biotechnology Industry Organization will begin the process of selecting a new president at its Feb. 23 board meeting in New York

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong

Table

View full table

Tags:
UsernamePublicRestriction

Register

PS043554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By